CorDynamics has expertise in multiple ‘gold-standard’ methods to study the pathology of pulmonary arterial hypertension (PAH) and investigate potential therapies.

DRUG DISCOVERY

Two proven PAH models available for customized study design:

Monocrotaline-Induced PAH Model
Rat model that allows for the evaluation of compounds in both prevention and reversal modes.

  • Right ventricular hypertrophy and pulmonary edema are apparent by 3 weeks
  • Increased pulmonary vessel wall medial thickness correlates with an elevated pulmonary arterial pressure
  • Often used for screening multiple compounds

Hypoxia + VEGF-Antagonist Induced PAH Model
Rat model that allows for the interrogation of test articles in the most robust small animal preclinical model available.

  • Pulmonary arterial wall thickening and occlusion of arterioles develops due to endothelial cell overgrowth
  • Right ventricular hypertrophy and pulmonary edema are apparent by 3 weeks
  • Gold-standard model that provides pathology most similar to human PAH